Excluding Inappropriate Treatment Approaches in NSCLC
Watch
Durvalumab Consolidation in NSCLC: The PACIFIC Trial
Managing CRT-Related Adverse Events in NSCLC
NSCLC: Optimal Imaging Following CRT
NSCLC Management Before and After the PACIFIC Trial
Case Overview: A Man With Stage IIIA NSCLC
Stage IIIA Unresectable NSCLC After Chemoradiotherapy
Examining the Use of CDK4/6 Inhibitors in HER2-Negative Breast Cancer
Debu Tripathy, MD, discusses the use of CDK4/6 inhibitors for the treatment of HER2-negative breast cancer based on the results from the phase III MONALEESA-7 trial.
Treating Stage IV Right-Sided CRC Beyond Progression
Frontline Therapy for Stage IV Right-Sided CRC
Molecular Testing and Tumor Sidedness in CRC
Diagnosing and Managing Stage IV Right-Sided CRC
A 75-Year-Old Man With Right-Sided mCRC
Future Developments & Screening Recommendations in CRC
Treatment Strategies for Left-Sided KRAS-Mutated CRC
Considerations for Managing an Atypical Patient With CRC
KRAS-Mutated Metastatic CRC
Next Steps for CAR T Cells in B-Cell Lymphomas
Victor A. Chow, MD, discusses the next steps for chimeric antigen receptor T-cell therapy in patients with B-cell lymphomas.
Managing Immunotherapy Toxicities in Melanoma
Michael A. Postow, MD, shares advice to community oncologists on managing the side effects of immunotherapy in patients with melanoma.
Looking to the Future of PARP Inhibitors in CRPC
Tanya Dorff, MD, discusses recent data with olaparib (Lynparza) in castration-resistant prostate cancer and the future role of PARP inhibitors in this disease.<br />
Assessing the Role of Darolutamide in CRPC
Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses takeaways from the ARAMIS study of darolutamide in patients with nonmetastatic castration-resistant prostate cancer.
NSCLC Stage III Unmet Needs and Practical Advice
Durvalumab Following Chemoradiotherapy and Surgery
PACIFIC Trial Implications Concerning NSCLC Mutations
Implications of Durvalumab Following PACIFIC Update
The Impact of the PACIFIC Trial and Updated Analysis
The Unprecedented Data of Next-Generation Sequencing
Immune Checkpoint Therapy Overview for Stage III NSCLC
Treatment Options for Stage III Unresectable NSCLC After Chemoradiotherapy
Lung Cancer
Safety Findings for Axi-Cel in Patients With DLBCL
Brian T. Hill, MD, PhD, discusses the safety findings from the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19, axi-cel) in patients with diffuse large B-cell lymphoma.
